TY - JOUR
T1 - Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus-a double-blind controlled study
AU - Yeh, T. F.
AU - Luken, J. A.
AU - Thalji, A.
AU - Raval, D.
AU - Carr, I.
AU - Pildes, R. S.
N1 - Funding Information:
From the Division of Neonatology and Pediatric Cardiology, Cook County Children's Hospital, The University of Illinois College of Medicine, and The Chicago Medical School. Supported in part by a grant from the Children "s Heart Research Foundation. Presented in part at the Annual Meeting of the Society for Pediatric Research, May 3, 1979, Atlanta, Georgia. *Reprint address: Division of Neonatology, Cook County Children's Hospital, 700 S. Wood St., Chicago, 1L 60612.
PY - 1981/1/1
Y1 - 1981/1/1
N2 - A double-blind controlled trial of intravenous indomethacin therapy was performed using a group of 55 premature infants (27 placebo, 28 indomethacin) with a significant persistent ductus arteriosus. Indomethacin administration at a mean postnatal age of 8.9 days was followed by a significant effect on PDA in 89%; 75% of successes were attributable to indomethacin and 25% to spontaneous effects, an improvement by indomethacin of 86% in infants not undergoing spontaneous improvement. The shortterm side effects of indomethacin were transient; urinary output and serum sodium concentration decreased and serum potassium concentration increased. Indomethacin administration was associated with a decreased need for assisted ventilation and a decreased need for surgical closure of PDA. There was no significant difference between the placebo and indomethacin groups in mortality and bronchopulmonary dysplasia morbidity. The infants who developed BPD had higher RDS scores and lower PO2 values, requiring higher F1O2s with four hours of birth than those who did not develop BPD, indicating a more severe underlying pulmonary disability present at birth.
AB - A double-blind controlled trial of intravenous indomethacin therapy was performed using a group of 55 premature infants (27 placebo, 28 indomethacin) with a significant persistent ductus arteriosus. Indomethacin administration at a mean postnatal age of 8.9 days was followed by a significant effect on PDA in 89%; 75% of successes were attributable to indomethacin and 25% to spontaneous effects, an improvement by indomethacin of 86% in infants not undergoing spontaneous improvement. The shortterm side effects of indomethacin were transient; urinary output and serum sodium concentration decreased and serum potassium concentration increased. Indomethacin administration was associated with a decreased need for assisted ventilation and a decreased need for surgical closure of PDA. There was no significant difference between the placebo and indomethacin groups in mortality and bronchopulmonary dysplasia morbidity. The infants who developed BPD had higher RDS scores and lower PO2 values, requiring higher F1O2s with four hours of birth than those who did not develop BPD, indicating a more severe underlying pulmonary disability present at birth.
UR - http://www.scopus.com/inward/record.url?scp=0019366120&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0019366120&partnerID=8YFLogxK
U2 - 10.1016/S0022-3476(81)80560-4
DO - 10.1016/S0022-3476(81)80560-4
M3 - Article
C2 - 7005415
AN - SCOPUS:0019366120
SN - 0022-3476
VL - 98
SP - 137
EP - 145
JO - The Journal of Pediatrics
JF - The Journal of Pediatrics
IS - 1
ER -